Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study.

ABSTRACT:

Aims

Inflammation is postulated to be a key pathogenic mechanism in heart failure with preserved ejection fraction (HFpEF). Soluble urokinase plasminogen activator receptor (suPAR), a regulator of innate immune activity, is associated with incident heart failure; however, its role in HFpEF remains unclear. We aimed to elucidate the role of suPAR in HFpEF outcomes.

Methods

In this secondary analysis of the TOPCAT trial's North American cohort, suPAR was measured at baseline and 1 year in a subset of patients with HFpEF (n = 406) treated with either spironolactone or placebo. We assessed the association between suPAR levels and adverse outcomes, whether spironolactone influenced suPAR levels and whether the association between spironolactone and outcomes is dependent on suPAR

SUBMITTER: Hutten CG 

PROVIDER: S-EPMC12719802 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature